Suneva Medical Unveils New Regenica® Revitalizing Eye Creme

- First and only eye creme formulated with Multipotent Resignaling Complex (MRCx™) next generation growth factor technology added to Regenica® skin care line

- Regenica® Revitalizing Eye Creme is clinically proven to decrease the appearance of lines and wrinkles in the crow's feet and under eye areas

- More than 80% of patients who participated in the product's clinical research study said they would recommend Regenica Revitalizing Eye Creme to a friend or purchase it themselves

News provided by

Suneva Medical, Inc.

Jun 11, 2015, 09:00 ET

SAN DIEGO, June 11, 2015 /PRNewswire/ -- Suneva Medical, Inc., a privately-held aesthetics company, today introduced Regenica® Revitalizing Eye Crème, the first and only eye crème developed with the combination of MRCx™ next generation growth factor technology, advanced peptides, powerful antioxidants and moisturizing agents. Regenica® Revitalizing Eye Crème is specifically formulated for the delicate skin around the eye and is clinically proven to decrease the appearance of lines and wrinkles in the crow's feet and under eye areas. The crème is the latest addition to the Regenica® skin care line, a family of next generation anti-aging products that help prevent and reverse signs of aging.

Regenica Revitalizing Eye Creme is the first and only eye creme formulated with Multipotent Resignaling Complex (MRCx) next generation growth factor technology

"MRCx™ growth factor technology is designed to enhance the skin's natural repair and renewal mechanisms, which makes this eye crème an ideal solution for erasing the look of fine lines, wrinkles and puffiness, as well as the appearance of dark under eye circles," said Dr. Michael Gold, dermatologist and key investigator in the clinical research for Regenica®. "Using a crème made specifically for your eyes is an essential component to a balanced skin care regimen and Regenica® Revitalizing Eye Crème is an excellent option to consider because it packs in growth factors. The product's clinical research showed high patient satisfaction in which more than 80% of study subjects would recommend the Revitalizing Eye Crème to a friend or purchase it themselves."¹

According to the American Academy of Dermatology (AAD), wrinkle creams, eye serums and other anti-aging skin care products can help diminish signs of aging.² As the only skin care line infused with MRCx™ next generation growth factor technology, Regenica's® formulation helps supplement the skin's natural anti-aging properties, which decline with age, to maintain a youthful and radiant complexion. In a clinical study, more than half of the subjects who used Regenica® Revitalizing Eye Crème noted improvement in the hydration of the skin in the under eyes and crow's feet areas. Many subjects also felt improvement in the appearance of under eye fatigue and the severity of crow's feet lines and wrinkles. At the conclusion of the study, investigators rated 63% of subjects as "much improved/improved" overall.¹

"Expanding the Regenica® line with an eye crème introduces another MRCx™ product breakthrough for the skin care industry," said Nicholas L. Teti, Jr., Chairman and Chief Executive Officer at Suneva Medical. "Regenica® Revitalizing Eye Crème was developed using the latest technological and scientific methods for truly effective eye area treatment that offers beautiful results."

The popular Regenica® product line includes Regenica® Renew SPF 15, Regenica® Replenishing Crème, Regenica® Repair Complex, Regenica® Recovery Gel and now the new Regenica® Revitalizing Eye Crème. To learn more about Regenica®, visit www.regenica.com or follow on Facebook: www.facebook.com/regenicaskincare, Twitter: @RegenicaSkin and Instagram: RegenicaSkincare.

For more information on Suneva Medical, visit www.sunevamedical.com.

Regenica® and MRCx™ are trademarks of Suneva Medical, Inc.

About Suneva Medical, Inc.

Suneva Medical, Inc. is a privately-held aesthetics company focused on developing, manufacturing and commercializing novel, differentiated products for the general dermatology and aesthetic markets. The innovative aesthetics leader markets Bellafill®, the only dermal filler on the market that is approved by the U.S. Food and Drug Administration for the correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheek in patients over the age of 21 years. In markets outside the U.S., Bellafill® is only approved for the correction of nasolabial folds. The company markets Bellafill® in the U.S. and Canada; ArteFill® in South Korea and Singapore; Regenica® skin care in the U.S. and Canada; and ReFissa® tretinoin cream in the U.S. ArteFill® was rebranded to Bellafill® in the U.S. to reflect the transformational outcomes this unique product can provide to patients seeking correction of their acne scars and nasolabial folds. For more information, visit www.sunevamedical.com.

¹Clinical data on file
²American Academy of Dermatology, https://www.aad.org/dermatology-a-to-z/health-and-beauty/every-stage-of-life/adult-skin/how-to-create-an-anti-aging-skin-care-plan

Photo - http://photos.prnewswire.com/prnh/20150610/222336

SOURCE Suneva Medical, Inc.